Today is #AutisticPrideDay! We join the #autism community today – and everyday – to celebrate the diversity of individuals with ASD and the endless opportunities and differences within the autistic community! #autismawareness #autsimacceptance #autismpride

On #Juneteenth, we recognize the commemoration of the ending of slavery in the U.S, and honor this day with reflection and hope. #FreedomDay

Today we announced that we have received a 2nd research grant from michaeljfox.org for #Parkinsons Research. This funding will support further preclinical development of AX-5006 with Phase 1 clinical trial initiation anticipated in 2024. Learn more: bit.ly/3qKobZg

Join us at the 8th Microbiome_Movement #Microbiome Movement Drug Development Summit, June 28-30 in Boston! Our VP, Head of Preclinical R&D, Becca Senter, will present on the development of AX-5006 as a potential treatment for #ParkinsonsDisease. Learn more: microbiome-summit.com

#Autism is a brain-based disorder that is characterized by social-communication challenges and restricted and repetitive behaviors, activities and interests. Learn more from ASF: bit.ly/43Y6rsh #AutismSpectrumDisorder

Today our VP, Head of Preclinical R&D, Becca Senter, will present on the development of AX-5006 as a potential treatment for #ParkinsonsDisease at the 8th Microbiome_Movement #Microbiome Movement Drug Development Summit! Learn more: microbiome-summit.com #Parkinsons

Wishing you a safe, restful and happy 4th of July from the Axial team!

We’re thrilled to be part of WuXi AppTec's BOLD: Innovation That Matters series on July 27! In the CNS spotlight session, our CEO Stew Campbell will discuss how we are #TakingBoldAction by harnessing groundbreaking #microbiome science: bit.ly/43s85kM

We are excited to participate in today’s WuXi AppTec’s BOLD: Innovation That Matters online series! Our CEO Stew Campbell discusses our microbiome-based therapies during the spotlight session “The Next Wave of CNS Disease Therapeutics”: bit.ly/43s85kM #TakingBOLDAction

This week, our CEO and head of R&D Stewart Campbell and our scientific founder and Caltech professor Dr. Sarkis Mazmanian will present at the Global Engage 7th #Microbiome R&D and Business Collaboration Congress Asia in South Korea. Learn more: global-engage.com/event/microbio…

Today we announced completion of enrollment in our Phase 2b #clinicaltrial of AB-2004, a first-in-class oral gut-targeted small molecule therapeutic designed to treat irritability associated with #autism. We look forward to sharing data in 1Q 2024: bit.ly/48m3Cnk

Happy Halloween from Axial! 🎃 Wishing our team and community a safe and fun-filled Halloween with great costumes, sweet treats, and laughter!

Next week, Rebecca Senter, PhD, Axial’s VP, Head of Preclinical R&D, will present on AX-5006 for the treatment of #ParkinsonsDisease and join a panel on #microbiome modulation at Microbiome Connect in Boston: bit.ly/3QRZ7dw #MicrobiomeConnect #MicrobiomeConnectUSA

Today, Rebecca Senter, PhD, Axial’s VP, Head of Preclinical R&D, is presenting on AX-5006 for the treatment of #ParkinsonsDisease and participating in a panel discussion at Microbiome Connect in Boston: bit.ly/3QRZ7dw #MicrobiomeConnect #MicrobiomeConnectUSA #Microbiome

Happy Holidays from the Axial team! Wishing everyone a restful, happy and healthy holiday season! #HappyHolidays #SeasonsGreetings

Next week, Axial’s CEO, Stewart Campbell, PhD, will participate in the Longwood Healthcare Leaders CEO Conference and the 2024 #BiotechShowcase. We look forward to sharing more about our mission to develop #microbiome therapeutics! bit.ly/48sPuZm #BioWeekSF #JPM24

Today at the Longwood Healthcare Leaders San Francisco CEO Conference, Stewart Campbell, PhD, Axial’s CEO, will participate in a panel discussion, “Advancing Research into the Clinic,” at 1:30 p.m. PT. Learn more: longwoodhealthcareleaders.com/sfceo #LongwoodHealthcareLeaders #BioWeekSF #JPM24

Axial’s CEO Stewart Campbell will give a corporate presentation at the 2024 #BiotechShowcase in San Francisco today at 10:30 a.m. PT. Learn more: informaconnect.com/biotech-showca… #BioWeekSF #JPM24

This week at the 2024 #BiotechShowcase, Axial's CEO Stewart Campbell presented on our mission to advance a pipeline of gut-targeted small molecule therapies in areas of significant unmet need incl. #autism and Parkinson’s disease. Learn more: axialtx.com #microbiome

Axial’s Vice President, Head of Preclinical R&D, Becca Senter is presenting tomorrow at the 2024 AD/PD - Advances in Science & Therapy International Conference on #Alzheimers and #Parkinsons Disease in Lisbon, Portugal. Learn more: adpd.kenes.com #ADPD2024